secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0000879407-26-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed
---------------------------------------------------------------------

- Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.
- REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.
- Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.
- Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.
- Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/0000879407-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/arwr-20260205.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer